Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 5/20 | 0.57 |
| ▸ | FNTA | P49354 | 3/20 | 0.55 |
| ▸ | FNTB | P49356 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599453 | 0.86 | KDM4E (0.56) | ALDH1A1MEN1KMT2AHTR2CKDM4E | |
| SCHEMBL6922520 | 0.85 | MAPK14 (0.47) | ALDH1A1MEN1KMT2AHTR2CFNTA | |
| SCHEMBL6927839 | 0.84 | MAPK14 (0.47) | ALDH1A1MEN1KMT2AHTR2CFNTA | |
| SCHEMBL27527405 | 0.84 | FNTA (0.64) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR2C | |
| SCHEMBL6926367 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR2C | |
| SCHEMBL6926641 | 0.81 | HTR2C (0.55) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR2C | |
| SCHEMBL6975190 | 0.76 | FNTA (0.69) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR2C | |
| SCHEMBL6599085 | 0.74 | MEN1 (0.56) | ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6930103 | 0.73 | FNTA (0.67) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR2C | |
| SCHEMBL30163469 | 0.72 | HTR2C (0.54) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1188407-C | Imidazole derivatives with inhabiting activity to transterasa and preparing method thereof | LG CHEMICAL LTD (KR) | 2005-02-09 | — | — | CN | disclosed |
| EP-1169320-B1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD (KR) | 2004-09-22 | — | — | EP | disclosed |
| CN-1158277-C | Farnesyl transferase inhibitor with piperidine structure and preparation method thereof | LG��ѧ��ʽ���� | 2004-07-21 | — | — | CN | disclosed |
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-6511978-B1 | For treating cancer, restenosis, atherosclerosis or viral infections | LG LIFE SCIENCES, LTD. (KR) | 2003-01-28 | — | — | US | disclosed |
| EP-1058683-B1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PIPERIDINE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2002-12-04 | — | — | EP | disclosed |
| EP-1169320-A4 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD (KR) | 2002-10-30 | — | — | EP | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6436960-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS AND INFECTIONS FROM HEPATITIS DELTA AND RELATED VIRUSES. | LG CHEMICAL LTD. (KR) | 2002-08-20 | — | — | US | disclosed |
| EP-1169320-A1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG Chem Investment, Ltd. (KR) | 2002-01-09 | — | — | EP | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
| CN-1289331-A | Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof | LG CHEMICAL LTD (KR) | 2001-03-28 | — | — | CN | disclosed |
| CN-1279680-A | Imidazole derivatives having farnesyl transferase inhibitory activity and process for producing the same | LG CHEMICAL LTD (KR) | 2001-01-10 | — | — | CN | disclosed |
| WO-2000064891-A1 | FARNESYL TRANSFERASE INHIBITORS HAVING A PYRROLE STRUCTURE AND PROCESS FOR PREPARATION THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | ALDH1A1 646/4885MEN1 523/4885KMT2A 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.